Literature DB >> 8889578

Glucocerebrosidase (Gaucher disease).

E Beutler1, T Gelbart.   

Abstract

Gaucher disease is the most common glycolipid storage disorder, characterized by storage of the glycolipid, glucocerebroside in the liver, spleen, and marrow. The most prevalent form of Gaucher disease is designated type I (MIM 230800). Patients with type I disease may have hepatomegaly, splenomegaly, bone lesions, and less commonly, lung disease, but are free of neurological involvement. Types II (MIM 230900) and III (MIM 2310000), the acute infantile and juvenile forms, respectively, of Gaucher disease, are characterized by the fact that the central nervous system is affected.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8889578     DOI: 10.1002/(SICI)1098-1004(1996)8:3<207::AID-HUMU2>3.0.CO;2-6

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  17 in total

1.  Mutation analysis in 46 British and Irish patients with Gaucher's disease.

Authors:  C E Hatton; A Cooper; C Whitehouse; J E Wraith
Journal:  Arch Dis Child       Date:  1997-07       Impact factor: 3.791

2.  Binding of 3,4,5,6-tetrahydroxyazepanes to the acid-β-glucosidase active site: implications for pharmacological chaperone design for Gaucher disease.

Authors:  Susan D Orwig; Yun Lei Tan; Neil P Grimster; Zhanqian Yu; Evan T Powers; Jeffery W Kelly; Raquel L Lieberman
Journal:  Biochemistry       Date:  2011-11-14       Impact factor: 3.162

Review 3.  Nanomedicine: clinical applications of polyethylene glycol conjugated proteins and drugs.

Authors:  Suphiya Parveen; Sanjeeb K Sahoo
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

4.  Effects of pH and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability.

Authors:  Raquel L Lieberman; J Alejandro D'aquino; Dagmar Ringe; Gregory A Petsko
Journal:  Biochemistry       Date:  2009-06-09       Impact factor: 3.162

5.  The N370S (Asn370-->Ser) mutation affects the capacity of glucosylceramidase to interact with anionic phospholipid-containing membranes and saposin C.

Authors:  Rosa Salvioli; Massimo Tatti; Susanna Scarpa; Sabrina Maria Moavero; Fiorella Ciaffoni; Federica Felicetti; Christine R Kaneski; Roscoe O Brady; Anna Maria Vaccaro
Journal:  Biochem J       Date:  2005-08-15       Impact factor: 3.857

6.  Coinheritance of Gaucher disease and α-thalassemia resulting in confusion between two inherited hematologic diseases.

Authors:  Ebrahim Miri-Moghaddam; Arash Velayati; Majid Naderi; Nahid Tayebi; Ellen Sidransky
Journal:  Blood Cells Mol Dis       Date:  2010-09-16       Impact factor: 3.039

Review 7.  The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement.

Authors:  T M Cox; J M F G Aerts; G Andria; M Beck; N Belmatoug; B Bembi; R Chertkoff; S Vom Dahl; D Elstein; A Erikson; M Giralt; R Heitner; C Hollak; M Hrebicek; S Lewis; A Mehta; G M Pastores; A Rolfs; M C Sa Miranda; A Zimran
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

8.  A Guided Tour of the Structural Biology of Gaucher Disease: Acid-β-Glucosidase and Saposin C.

Authors:  Raquel L Lieberman
Journal:  Enzyme Res       Date:  2011-11-22

9.  Mapping the genetic and clinical characteristics of Gaucher disease in the Iberian Peninsula.

Authors:  Pilar Giraldo; Pilar Alfonso; Pilar Irún; Laura Gort; Amparo Chabás; Lluïsa Vilageliu; Daniel Grinberg; Clara M Sá Miranda; Miguel Pocovi
Journal:  Orphanet J Rare Dis       Date:  2012-03-19       Impact factor: 4.123

Review 10.  Progressive myoclonic epilepsy.

Authors:  Mary L Zupanc; Benjamin Legros
Journal:  Cerebellum       Date:  2004       Impact factor: 3.648

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.